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Abstract Enterococci are an increasingly important
cause of nosocomial infections. While the clinical impact
of enterococci in cases of bacteremia and super-infections
in selected patient populations has been well-established,
their role as primary pathogens in polymicrobial intra-
abdominal infections remains controversial. While it has
been suggested that the presence of enterococci increases
the rate of infectious post-operative complication, it has
also been demonstrated that polymicrobial intra-abdom-
inal infections involving enterococci can be treated
successfully with appropriate surgical drainage and
antibiotics, such as cephalosporins, that are not active
against enterococci. Therefore, the question arises of
whether or not antibiotic coverage against enterococci
should be included in the empirical treatment of perito-
nitis in certain high-risk patient populations. An extensive
literature review revealed some evidence arguing in
favour of using empirical therapy with enterococcal
coverage for intra-abdominal infections in the following
cases: (i) immunocompromised patients with nosocomial,
post-operative peritonitis; (ii) patients with severe sepsis
of abdominal origin who have previously received
cephalosporins and other broad-spectrum antibiotics se-
lecting for Enterococcus spp.; (iii) patients with perito-
nitis and valvular heart disease or prosthetic intravascular
material, which place them at high risk of endocarditis.
The ideal therapeutic regimen for these high-risk patients
remains to be determined, but empirical therapy directed
against enterococci should be considered.
Introduction
Peritonitis is a frequent and life-threatening disease [1].
During the last century, however, great progress has been
made in the management of this condition [2]. Although
antimicrobial treatment has certainly helped to improve
patient outcome [3, 4], adequate source control by early
surgical intervention remains the cornerstone of treatment
[5, 6].
While enterococci are an increasingly important cause
of nosocomial infections, their clinical significance in
peritonitis has been the subject of a long-lasting and
ongoing debate [7, 8, 9, 10, 11]. Several recent articles
have attempted to better delineate the profile of patient
populations at high risk of invasive enterococcal perito-
nitis and have suggested that empiric anti-enterococcal
coverage in these patients may be beneficial [12, 13].
Based on a selection of relevant articles, the present
review attempts to summarise published evidence arguing
in favour of empiric anti-enterococcal coverage in
selected patient groups. More specifically, the following
questions are addressed: (i) What basic coverage is
absolutely needed in the empiric therapy of peritonitis?
(ii) Are enterococci able to cause treatment failures and
adverse outcomes in patients with intra-abdominal infec-
tion? (iii) Which surgical patients are at risk of entero-
coccal bacteremia? (iv) What is the potential impact of
inadequate enterococcal coverage in septic high-risk
patients? (v) What is the profile of patients for whom
empiric enterococcal coverage should be advocated?
What Basic Coverage is Required for Empiric Therapy
of Peritonitis?
The goals of antimicrobial therapy in the treatment of
peritonitis are as follows: (i) to prevent the local spread of
existing infection in the early phase; (ii) to control
bacteremia and avoid distant hematogenous spread (e.g.
hepatic abscess); and (iii) to reduce late complications
after bacterial intra-abdominal contamination (e.g. post-
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operative abscess). In cases of secondary peritonitis,
empiric antibiotic regimens should at least include
coverage of aerobic gram-negative bacteria in order to
decrease early mortality induced by bacterial endotoxins
causing septic shock; they should also include coverage of
anaerobic microorganisms to prevent the development of
late post-operative abscesses [10, 14]. Several clinical
studies performed in the 1970s showed that in the absence
of adequate anti-anaerobic coverage, the late complica-
tion rate after intra-abdominal infection was high, with an
incidence of post-operative abscesses of up to 30% [15,
16].
Ample evidence suggests that complicated, communi-
ty-acquired intra-abdominal infections involving mixed
flora can be treated with surgery and different classes of
antibiotics without consistent anti-enterococcal activity
(e.g. cephalosporins, fluoroquinolones) [11, 17, 18, 19,
20, 21, 22, 23]. For example, a review of six clinical trials
examining the use of antibiotics without in-vitro activity
against enterococci in the treatment of intra-abdominal
infections noted no cases of treatment failure due to
Enterococcus spp., despite the fact that 20–30% of
cultures grew enterococci [10]. Thus, the frequent prac-
tice of adding ampicillin or penicillin to cover entero-
coccal infection is not justified in most cases.
Conventional wisdom even argues against the necessity
of adding anti-enterococcal coverage if initial intra-
peritoneal cultures showed enterococcal growth [9].
Are Enterococci Able to Cause Treatment Failures
and Adverse Outcomes in Patients
with Intra-Abdominal Infection?
While the clinical impact of antibiotic-resistant entero-
cocci in bacteremia and super-infections in selected
patient populations (e.g., burn patients with infections
due to vancomycin-resistant enterococci) has been well
established [24, 25], the role of antibiotic-susceptible
enterococci as primary pathogens in polymicrobial intra-
abdominal infections is still controversial. Animal models
have shown that monomicrobial, intra-abdominal entero-
coccal infections have limited pathogenicity, since the
organism lacks virulence and the capacity to induce late
abscess formation [26, 27]. It has been postulated that
enterococci may express bacterial synergy and pro-
inflammatory activity only in the presence of more
virulent bacteria by inhibiting phagocytosis and intracel-
lular killing of those primary pathogens [28].
Clinical data about the harmful effect of enterococcal
peritonitis is also limited, since many types of organisms
are usually cultured from intra-abdominal infections. A
case series published 2 decades ago analysed enterococcal
breakthrough sepsis in 19 surgical patients and found a
crude case-fatality rate of 68% [29]. In 1995, the
secondary analysis of a randomised clinical trial involving
330 patients postulated that the presence of Enterococcus
spp. may be a marker for a complicated course in
hospitalised patients with peritonitis and that the presence
of this microorganism was associated with a higher
likelihood of treatment failure [30].
More recent studies have suggested that the presence
of enterococci increases the infectious post-operative
complication rate and even the risk of death [12, 13]. For
instance, Sitges-Serra et al. [13] have looked at post-
operative enterococcal infections after treatment of com-
plicated intra-abdominal sepsis. They found a high
proportion (50%; n=34) of enterococci in post-operative
peritonitis. Independent risk factors for enterococcal
infection were tertiary peritonitis, high severity of illness
and inappropriate empirical antibiotic coverage against
enterococci. Post-operative enterococcal infections were
associated with higher mortality (21% vs. 4%; P<0.001).
The authors of this study concluded that empirical
antibiotic therapy covering enterococci “should be con-
templated in some circumstances” [13]. Table 1 sum-
marises the different types of studies that have
investigated potential adverse outcomes associated with
enterococcal intra-abdominal infection.
Which Surgical Patients Are at Risk
of Enterococcal Bacteremia?
Most authorities agree that enterococcal bacteremia is a
clinical condition requiring adequate antibiotic treatment,
since serious adverse outcomes can arise [24]. In one case
series, 15% of all episodes of nosocomial enterococcal
Table 1 Overview of studies investigating whether enterococci are able to cause treatment failures and adverse outcomes
Type of study Reference, year Design and population Data
Experimental
animal study
[28], 1997 mice and rats with polymicrobial
peritonitis
evidence for a pro-inflammatory role of Enterococcus
faecalis
Case series [7], 1983 19 surgical patients breakthrough enterococcal sepsis associated with a
high case-fatality ratio
Cohort study [30], 1995 secondary analysis of a randomised
clinical trial (n=330)
presence of Enterococcus spp. associated with treatment
failure
Cohort study [12], 2002 120 critically ill patients with secondary
peritonitis
presence of Enterococcus spp. predictive of death; no
impact of antibiotic therapy
Cohort study [13], 2002 longitudinal observational study of
200 patients
enterococci often involved in postoperative infectious
complications
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bacteremia were complicated by endocarditis [31]. There-
fore, the following question arises: Have previous inves-
tigations already pre-defined the risk profile of surgical
patients at high risk of enterococcal bacteremia? Surpris-
ingly, although many studies have analysed the risk
factors for vancomycin-resistant enterococcal infections
[32, 33, 34] or the risk factors for enterococcal bacteremia
in hospital-wide studies [35, 36, 37], few studies have
analysed in detail the risk factors for enterococcal
bacteremia in surgical patients [38]. For instance, Barrall
et al. [39] performed a descriptive cohort study without
multivariable analysis and found that enterococcal bac-
teremia was preceded by antibiotic use, exposure to
central-venous catheters, other-organism bacteremia and
intra-abdominal operations. Clearly, more precise and
well-conducted studies are needed to better delineate the
risk profile of patients undergoing general surgery who
are at high risk of enterococcal bacteremia.
Immunocompromised patients permanently exposed to
the health-care setting are at high risk of enterococcal
bacteremia. It is a frequent infectious complication in
liver transplant patients having previously received
selective bowel decontamination, as previously shown
by Patel et al. [40]. In their large cohort study, among 405
liver transplant patients, 114 had bacteremia with any
type of microorganism and 52 had enterococcal bacter-
emia (incidence, 13%).
What Is the Potential Impact
of Inadequate Enterococcal Coverage
in High-Risk Patients with Enterococcal Sepsis?
Antibiotic selection pressure increases the risk of entero-
coccal super-infection and bacteremia either with drug-
susceptible or -resistant strains [34]. Enterococcal super-
infection may be prevented by avoiding prolonged
prophylactic or broad-spectrum therapeutic regimens
(such as those with cephalosporins) that lack anti-
enterococcal activity [41]. In cases of enterococcal sepsis
in critically ill patients, inadequate empiric antibiotic
therapy may increase the risk of death. As shown in a
prospective multicentre study among patients with mo-
nomicrobial enterococcal bacteremia, the receipt of
effective anti-enterococcal therapy within 48 hours inde-
pendently predicted survival (odds ratio [OR] for death,
0.21; 95% confidence interval [CI], 0.06–0.80) [24].
We performed a secondary analysis of a randomised
clinical trial of 904 patients with microbiologically
documented severe sepsis and found that inadequate
antimicrobial treatment of severe sepsis of abdominal
origin (n=123) was associated with a significantly
increased risk of death after adjusting for confounding
factors (OR, 2.8; 95%CI, 1.3–5.9); inadequately treated
enterococcal infection contributed to this increased risk
[42]. Certainly, new diagnostic approaches and interven-
tions aimed at improving the detection and treatment of
early gram-positive sepsis are urgently needed.
What Is the Profile of Patients for Whom Empiric
Enterococcal Coverage Should Be Advocated?
Figure 1 summarises a tentative proposal of those highly
selected patients who may benefit from empiric anti-
enterococcal coverage in case of secondary or tertiary
peritonitis. Although empiric therapy directed at entero-
cocci may not always be necessary, reasonable indica-
tions for specific therapy include the presence of septic
shock in patients pre-treated with cephalosporins, im-
munosuppressed patients at high risk of bacteremia,
presence of prosthetic heart valves, or persistent or
recurrent intra-abdominal infection with signs of severe
sepsis.
Presentation of an Exemplary Case History
in which Empiric Anti-Enterococcal Therapy
for Peritonitis was Considered Adequate and Beneficial
In June 2003, an 86-year-old female patient with a history
of type II diabetes, severe post-rheumatic valvulopathy
and secondary pulmonary arterial hypertension experi-
enced a first episode of moderate diverticulitis. She was
treated as an outpatient with 2 g of ceftriaxone i.v./day for
10 days without anaerobic coverage. After initial im-
provement, the patient was hospitalised 2 months later
with symptoms of lower abdominal pain, fever (38C)
and leukocytosis (18.5 G/l). On admission, there was no
peritonitis, but clinical exam revealed a recto-vaginal
fistula. An abdominal computed tomography scan showed
multiple small abscesses.
The patient refused surgical treatment and was treated
empirically with a combination of ceftriaxone and
metronidazole. Blood cultures grew Escherichia coli
sensitive to ceftriaxone. Despite antibiotic treatment, on
day 9 of hospitalisation she developed signs of peritonitis
and severe sepsis. Antibiotic treatment was immediately
changed to a broad-spectrum regimen covering Entero-
coccus faecalis, the presence of which was confirmed 4
Fig. 1 Tentative treatment recommendation for selected cases of
intra-abdominal infection where empiric coverage of enterococci
may be considered
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days later in two sets of blood cultures. The patient
improved and was discharged 18 days later without
surgical intervention. This case shows that empiric anti-
enterococcal coverage may be warranted and beneficial in
the presence of risk factors for enterococcal super-
infection and endocarditis.
Conclusions
Enterococcal infections are becoming increasingly preva-
lent, because of the widespread use of cephalosporins,
often neglected environmental reservoirs in the hospital
setting, and a greater number of immunosuppressed
patients [43]. Although many invasive enterococcal
infections are of intra-abdominal origin, the pathogenic
role of Enterococcus spp. in peritonitis remains contro-
versial. Many studies have demonstrated that polymicro-
bial intra-abdominal infections that contain enterococci
can be treated successfully with appropriate surgical
drainage and antibiotics such as cephalosporins that are
not active against enterococci. Therefore, in the recently
published IDSA-guidelines for the selection of antibiotic
therapy for complicated intra-abdominal infections,
strong evidence was cited against routine coverage of
Enterococcus spp. in community-acquired intra-abdomi-
nal infections [14].
In contrast, there is some evidence (although of rather
weak quality) to justify the use of empiric antibiotic
therapy covering enterococci in post-operative, nosoco-
mial peritonitis in certain high-risk patient populations.
Based on the literature review presented here, we found
evidence arguing in favour of using empirical enterococ-
cal coverage in the treatment of intra-abdominal infec-
tions in the following cases: (i) immunocompromised
patients with nosocomial, post-operative peritonitis; (ii)
patients with severe sepsis of abdominal origin who have
previously received cephalosporins or other broad-spec-
trum antibiotics selecting for Enterococcus spp.; (iii)
patients with peritonitis and valvular heart disease or
prosthetic intravascular material, which may increase the
risk of enterococcal endocarditis.
The ideal therapeutic regimen for these high-risk
patients remains to be determined, but empirical therapy
directed against enterococci should be considered. Ex-
tended-spectrum penicillins with anaerobic coverage may
be effective empiric regimens for those selected cases,
since they offer adequate therapy for mixed intra-
abdominal infections. In cases of confirmed enterococcal
bacteremia (without vancomycin resistance), patients
should be treated with bactericidal, combination antibiotic
therapy including a penicillin and an aminoglycoside.
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